DWRX2003

DRUG4 trials

Sponsors

Daewoong Pharmaceutical Co. LTD.

Conditions

COVID-19COVID-19 PatientsHealthy

Phase 1

To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19

Daewoong Pharmaceutical Co. LTD.Healthy

Start: 2020-08-31End: 2020-12-31Target: 32Updated: 2020-08-24

To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)

TerminatedNCT04541485

Daewoong Pharmaceutical Co. LTD.COVID-19 Patients

Start: 2020-12-04End: 2021-03-23Updated: 2021-09-23

To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003

Daewoong Pharmaceutical Co. LTD.COVID-19 Patients

Start: 2020-10-19End: 2021-06-30Target: 24Updated: 2020-10-19

Phase 2

Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

TerminatedNCT05226533

Daewoong Pharmaceutical Co. LTD.COVID-19

Start: 2022-03-31End: 2022-12-21Updated: 2023-02-10